RECRUITING

Addressing Genomic Disparities in Cancer Survivors

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this observational study is to increase genetic education and genetic testing for hereditary cancer risk among Black cancer survivors. The study will: 1. Test the effectiveness of a chatbot intervention (also called relational agent, or RA) vs. enhanced usual care (EUC) on engagement in genetic education and requests for genetic testing. 2. Evaluate the impact of the chatbot vs. EUC on the process that participants use to make decisions and evaluate effects on well-being (also called psychosocial outcomes). 3. Explore the ways (methods) that influence how participants experience the intervention. 4. Explore the feasibility of incorporating a Family Sharing Portal (FSP) for participants who receive a positive test result, to facilitate family communication of these test results and genetic testing of first-degree biological relatives after they have received genetic education by the RA. The main questions this study aims to answer are which group - the chatbot (RA) group or the EUC group - is more likely to request genetic testing and which group is more likely to get (engage with) genetic education. Participants will be randomly assigned to either the chatbot (RA) group or EUC group. This means each participant has an equal chance of being placed in either group, just like flipping a coin. Each group will receive genetic education and have an opportunity to request genetic testing. Researchers will compare the chatbot (RA) group and the EUC group to see which may request more GT (genetic testing) and which group engages more with genetic education.

Official Title

Addressing Genomic Disparities in Cancer Survivors

Quick Facts

Study Start:2024-07-31
Study Completion:2027-08-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06073626

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 18-80 years of age
  2. * Self-identify as Black or African American
  3. * At least 6-months post diagnosis with any of the following cancers: breast, ovarian, uterine, prostate, colorectal, pancreatic
  4. * Have not had genetic testing for hereditary cancer
  5. * Have received care at one of the participating sites in the prior five years
  6. * Meet National Comprehensive Cancer Network criteria for germline GT
  7. * Able to read and speak in English
  8. * Capable of providing informed consent
  9. * Have internet access (via smartphone, tablet or computer)
  10. * Comfortable using a computer or mobile phone independently to access information
  1. * Do not speak English
  2. * Unable to access the Internet
  3. * Have previously undergone germline genetic testing for hereditary cancer risk or previously had genetic counseling (GC) and declined genetic testing (GT)
  4. * Are unable to provide informed consent

Contacts and Locations

Study Contact

Erin Speiser, PhD, MA
CONTACT
732-675-1668
erin.speiser@rutgers.edu
Julie Chapman Greene, PhD, MPH
CONTACT
chapmaje@cinj.rutgers.edu

Principal Investigator

Anita Y Kinney, PhD, RN
PRINCIPAL_INVESTIGATOR
Director at Rutgers Cancer Institute

Study Locations (Sites)

Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, 20007
United States
Rutgers Cancer Institute
New Brunswick, New Jersey, 08901
United States

Collaborators and Investigators

Sponsor: Rutgers, The State University of New Jersey

  • Anita Y Kinney, PhD, RN, PRINCIPAL_INVESTIGATOR, Director at Rutgers Cancer Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-07-31
Study Completion Date2027-08-31

Study Record Updates

Study Start Date2024-07-31
Study Completion Date2027-08-31

Terms related to this study

Keywords Provided by Researchers

  • hereditary cancer
  • genetic testing
  • genetic education
  • relational agent
  • chatbot

Additional Relevant MeSH Terms

  • Hereditary Cancer
  • Genetic Testing